Pharmaxis Ltd
ASX:PXS.AX
Overview | Financials
Company Name | Pharmaxis Ltd |
Symbol | PXS.AX |
Currency | AUD |
Price | 0.028 |
Market Cap | 20,233,192 |
Dividend Yield | 0% |
52-week-range | 0.027 - 0.065 |
Industry | Drug Manufacturers—Specialty & Generic |
Sector | Healthcare |
CEO | Mr. Gary Jonathan Phillips BPharm, MBA |
Website | https://www.pharmaxis.com.au |
An error occurred while fetching data.
About Pharmaxis Ltd
Pharmaxis Ltd engages in the research, development, and commercialization of healthcare products for the treatment of fibrotic and inflammatory diseases worldwide. The company operates through two segments, Mannitol Respiratory Business and New Drug Development. It offers Bronchitol, an inhaled dry powder for the treatment of cystic fibrosis; and Aridol, an
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD